FDA approves new PET agent for finding neuroendocrine tumors

The U.S. Food and Drug Administration has approved a kit used to prepare and inject a PET imaging agent that can ferret out rare somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients.

Marketed by Advanced Accelerator Applications, the kit, to be called Netspot, represents the first clinical application of the radioactive probe drug Ga 68 dotatate, according to FDA. Read more.